儿童急性淋巴细胞白血病治疗相关骨毒性的遗传决定因素
本研究通过全外显子组测序发现PGAP2基因变异与儿童急性淋巴细胞白血病治疗相关骨坏死相关,并在独立队列中验证;BCL2L11和ACP1-SH3YL1位点变异与骨折相关,且受糖皮质激素暴露和门冬酰胺酶剂型等方案因素调节。转录组分析提示PGAP2异构体表达改变可能具有功能意义。
要点
- PGAP2变异与骨坏死及骨坏死-骨折联合表型相关,并在独立队列中验证。
- BCL2L11和ACP1-SH3YL1变异与骨折相关,存在协同效应并受方案因素调节。
- 遗传易感性与药物暴露需整合评估骨毒性风险。
核心结论
- PGAP2、BCL2L11和ACP1-SH3YL1变异是儿童ALL治疗相关骨毒性的临床相关预测因素,但其表现依赖治疗背景。
研究设计与样本
- 研究先通过全外显子组测序在发现队列中识别与骨坏死相关的遗传变异,并在独立复制队列中验证。
- 随后在更近期Dana-Farber癌症研究所治疗方案队列中评估新发现变异及既往候选基因关联。
- 转录组分析用于探索PGAP2在骨毒性患者中的异构体特异性表达变化。
主要发现
- PGAP2基因变异与骨坏死相关,并在独立复制队列中确认,两个队列均观察到患者和疾病特征的影响。
- BCL2L11和ACP1-SH3YL1位点变异与骨折相关,二者存在强协同效应,并受方案特异性因素显著调节。
- PGAP2变异与骨坏死-骨折联合表型相关。
- 转录组分析显示骨毒性患者中PGAP2存在异构体特异性表达改变,支持剪接或基因调控改变的功能作用。
临床怎么用
- 在儿童ALL治疗中可考虑整合PGAP2、BCL2L11和ACP1-SH3YL1变异信息与糖皮质激素暴露、门冬酰胺酶剂型等药物因素评估骨毒性风险。
局限性
- 遗传变异的临床表现依赖治疗背景,需进一步研究其分子机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Osteonecrosis and fractures are serious corticosteroid-induced bone toxicities in children treated for acute lymphoblastic leukemia, yet their genetic determinants remain incompletely defined. In this study, we aimed to identify novel genetic contributors to bone toxicity and to evaluate the robustness of both newly identified and previously established risk genotypes in more recent Dana-Farber Cancer Institute treatment protocols. Whole-exome sequencing was first performed in a discovery cohort to identify genetic variants associated with osteonecrosis. A novel association with a variant in the PGAP2 gene was identified and subsequently confirmed in an independent replication cohort, with effects of patient- and disease-related characteristics observed in both cohorts. Next, previously reported candidate gene-derived associations, together with this newly identified variant, were assessed in a more recent cohort to examine their relevance in contemporary treatment protocols. Variants in BCL2L11 and the ACP1-SH3YL1 locus were associated with bone fractures, with a strong synergistic effect and significant modulation by protocol-specific factors, particularly corticosteroid exposure and asparaginase formulation. The PGAP2 variant was associated with the combined osteonecrosis-fracture phenotype. Transcriptomic analyses revealed isoform-specific expression shifts in PGAP2 in patients with osteotoxicity, supporting a potential functional role for altered splicing or gene regulation. Together, our results provide insight into the pharmacogenomic architecture of osteotoxicity in ALL, demonstrating that PGAP2, BCL2L11, and ACP1-SH3YL1 variants remain clinically relevant predictors of bone toxicity across evolving treatment protocols. However, their clinical manifestations appear to be context-dependent, underscoring the importance of integrating genetic susceptibility with pharmacologic exposures and supporting further investigation of the underlying molecular mechanisms.
引用
- Abaji R, Gagné V, Espagne É, et al. Genetic Determinants of Treatment-Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia. Clin Pharmacol Ther. 2026. PMID: 42325004. doi:10.1002/cpt.70371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。